Jefferies Maintains Buy on BioMarin Pharmaceutical, Raises Price Target to $105

Benzinga · 3d ago
Jefferies analyst Akash Tewari maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Buy and raises the price target from $104 to $105.